2021 Gastrointestinal Cancers Symposium | Supplements And Featured Publications

Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers

February 25, 2021

Axel Grothey, MD, discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.

Trastuzumab Deruxtecan Slated for Study in HER2+ Gastric/GEJ Cancer

February 15, 2021

Fam-trastuzumab deruxtecan-nxki is under study alone and in combination for the treatment of patients with HER2-overexpressing locally advanced, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma in the ongoing phase 1b/2 DESTINY-Gastric03 trial.

Ivosidenib Induces OS Benefit in Advanced IDH1+ Cholangiocarcinoma

January 17, 2021

January 17, 2021 — Ivosidenib tablets led to a 21% reduction in the risk of death compared with placebo in previously treated patients with IDH1-mutant cholangiocarcinoma, according to the final overall survival analysis of the phase 3 ClarIDHy trial.

TAS-102 Plus Bevacizumab Improves OS in mCRC Ineligible for Intensive Therapy

January 17, 2021

January 16, 2021 - Trifluridine/tipiracil, when used in combination with bevacizumab, led to an improvement in overall survival over capecitabine/bevacizumab in the frontline treatment of patients with unresectable metastatic colorectal cancer who are not eligible for standard chemotherapy.

Frontline Bemarituzumab/mFOLFOX6 Combo Improves Survival in Advanced FGFR2b+ Gastric/GEJ Cancer

January 16, 2021

Bemarituzumab combined with mFOLFOX6 demonstrated a 56% reduction in the risk of disease progression or death compared with placebo and mFOLFOX6 as a frontline treatment in select patients with FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Pembrolizumab Triplet Appears Effective in HER2+ Advanced Gastric, GEJ Cancer Regardless of PD-L1 Status

January 15, 2021

January 15, 2021 - Pembrolizumab with trastuzumab and the combination of cisplatin and capecitabine appeared effective in treating HER2-positive advanced gastric and gastroesophageal junction cancer, regardless of a patient’s PD-L1 status.

Patritumab Deruxtecan Poised for Phase 2 Exploration in HER3+ Advanced CRC

October 26, 2020

The novel HER3-targeted antibody-drug conjugate patritumab deruxtecan is currently being investigated in a phase 2 trial as a potential treatment for patients with advanced or metastatic colorectal cancer who are resistant, refractory, or intolerant to at least 2 previous lines of systemic therapy.